Form 4: Evoke Pharma Director Sells Shares, Options in Merger

Evoke Pharma Director Todd C. Brady reported the disposition of common stock and the cash conversion of stock options following the company's acquisition by QOL Medical, LLC.

Summary

• Todd C. Brady, a Director of Evoke Pharma Inc. (EVOK), reported changes in beneficial ownership.
• On December 16, 2025, a tender offer by QOL Medical, LLC and QOL-EOS Merger Sub, Inc. to acquire all outstanding shares of Evoke Pharma Common Stock for $11.00 per share in cash was completed.
• Following the tender offer, on December 17, 2025, Merger Sub merged with Evoke Pharma, making Evoke Pharma a wholly-owned subsidiary of QOL Medical, LLC.
• Immediately prior to the merger's effective time, all outstanding stock options held by the reporting person accelerated, became fully vested, and were automatically canceled.
• These options were converted into a cash payment equal to the number of shares underlying the option multiplied by the difference between the $11.00 Offer Price and the option's per share exercise price.
• The reporting person disposed of 27 shares of Common Stock.
• Stock options with exercise prices of $5.41, $4.45, and $3.453, underlying 1,218, 5,833, and 1,187 shares respectively, were converted to cash.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger and tender offer, resulting in the reporting person cashing out their equity and options. This is a definitive event, not a performance update, and the transaction was executed as planned, providing liquidity to shareholders.

Positives

• The reporting person received cash for common stock and stock options at the Offer Price of $11.00 per share.
• Stock options accelerated and became fully vested, allowing for immediate cash realization for the reporting person.

Negatives

• Evoke Pharma Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary.
• Shareholders no longer hold equity in Evoke Pharma Inc.

Future Outlook

The filing reports a completed transaction, indicating Evoke Pharma Inc. is now a wholly-owned subsidiary of QOL Medical, LLC. There are no forward-looking statements regarding Evoke Pharma as an independent public entity.

Industry Context

This event represents a consolidation within the pharmaceutical or medical sector, where a publicly traded company with specific assets or market focus is acquired by another entity. Such acquisitions are a common strategy for growth or market expansion.

Comparison to Industry Standards

• The acquisition price of $11.00 per share would typically be assessed against Evoke Pharma's unaffected share price, analyst price targets, and valuations of comparable M&A transactions in the specialty pharmaceutical industry.
• The premium offered to shareholders, if any, over the pre-announcement trading price is a key indicator of the transaction's attractiveness.
• The use of a tender offer followed by a short-form merger is a standard and efficient mechanism for acquiring public companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $11.00 per share in cash for their common stock and cash for their options, losing their equity stake in Evoke Pharma.
• Employees: While not directly addressed, a change in ownership can lead to integration efforts and potential changes in employment terms or structure.
• Customers/Suppliers: Not directly addressed, but the change in ownership could impact future business relationships or product strategies.

Next Steps

• Evoke Pharma Inc. will operate as a wholly-owned subsidiary of QOL Medical, LLC.
• The reporting person has completed their transaction related to the merger.

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, Merger, Tender Offer, Form 4, Beneficial Ownership, Stock Options, Director, Acquisition, Cash Out